Literature DB >> 27492104

Higher-order aberrations 1 year after corneal collagen crosslinking for keratoconus and their independent effect on visual acuity.

Robert P L Wisse1, Stijn Gadiot2, Nienke Soeters2, Daniel A Godefrooij2, Saskia M Imhof2, Allegonda van der Lelij2.   

Abstract

PURPOSE: To evaluate the effect of corneal collagen crosslinking (CXL) in progressive keratoconus patients on higher-order aberrations (HOAs) and the effect of change in HOAs on visual acuity between baseline and 1 year after CXL.
SETTING: Tertiary academic referral center, Utrecht, the Netherlands.
DESIGN: Prospective cohort study.
METHODS: This study included consecutive keratoconus patients who were treated with epithelium-off CXL and followed for a minimum of 1 year. The following corneal HOAs were measured with Scheimpflug tomography (Pentacam HR type 70900): coma, trefoil, spherical aberration, and total corneal HOAs. A 2-tailed paired-samples t test was used to compare baseline and postoperative aberrations. Multivariable linear regression was applied to assess the independent effects of HOA subtypes on changes in uncorrected (UDVA) and corrected (CDVA) distance visual acuity.
RESULTS: Overall, the degree of corneal HOAs in the patient cohort (N = 187) was relatively unchanged after CXL, with a mean change of -1.34% (P = .272). Horizontal coma contributed most to the total amount of HOAs but was virtually unchanged on average. The HOA subtype of spherical aberrations decreased significantly (-15.68%) (P < .001). There was no effect of the change in HOAs on the change in CDVA; however, there was a significant effect of the change in horizontal coma on the change in UDVA (P = .003; B -0.475).
CONCLUSIONS: Corneal HOAs in general were relatively unchanged from baseline to 1 year after CXL in eyes with progressive keratoconus. A change in horizontal coma had a strong and independent effect on UDVA. FINANCIAL DISCLOSURE: None of the authors has a financial or proprietary interest in any material or method mentioned.
Copyright © 2016 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27492104     DOI: 10.1016/j.jcrs.2016.04.021

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  7 in total

Review 1.  Adverse events after riboflavin/UV-A corneal cross-linking: a literature review.

Authors:  Sebastiano Serrao; Giuseppe Lombardo; Marco Lombardo
Journal:  Int Ophthalmol       Date:  2021-08-27       Impact factor: 2.031

2.  The evaluation of a web-based tool for measuring the uncorrected visual acuity and refractive error in keratoconus eyes: A method comparison study.

Authors:  Marc B Muijzer; Janneau L J Claessens; Francesco Cassano; Daniel A Godefrooij; Yves F D M Prevoo; Robert P L Wisse
Journal:  PLoS One       Date:  2021-08-18       Impact factor: 3.240

3.  Corneal higher-order aberration changes after accelerated cross-linking for keratoconus.

Authors:  Abdelrahman Salman; Marwan Ghabra; Taym R Darwish; Obeda Kailani; Hussein Ibrahim; Hakam Ghabra
Journal:  BMC Ophthalmol       Date:  2022-05-18       Impact factor: 2.086

4.  Mesopic visual quality after accelerated corneal cross linking: A 12-month follow-up study.

Authors:  Hassan Hashemi; Soheila Asgari
Journal:  J Curr Ophthalmol       Date:  2016-10-21

5.  High-resolution wavefront-guided surface ablation with corneal cross-linking in ectatic corneas: a pilot study.

Authors:  Gustavo E Tamayo; Claudia Castell; Pilar Vargas; Eduardo Polania; Juliana Tamayo
Journal:  Clin Ophthalmol       Date:  2017-10-03

6.  Higher order optical aberrations and visual acuity in a randomized controlled trial comparing transepithelial versus epithelium-off corneal crosslinking for progressive keratoconus.

Authors:  Daniel A Godefrooij; Mustapha El Kandoussi; Nienke Soeters; Robert Pl Wisse
Journal:  Clin Ophthalmol       Date:  2017-10-30

7.  Five-Year Long-Term Results of Standard Collagen Cross-Linking Therapy in Patients with Keratoconus

Authors:  Yelda Yıldız Taşçı; Güzin Taşlıpınar; Demet Eyidoğan; Özge Saraç; Nurullah Çağıl
Journal:  Turk J Ophthalmol       Date:  2020-08-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.